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Abstract
Background: Resident macrophages in OA synovial tissue contribute to synovitis through pro-inflammatory
mediators driving cartilage loss. What remains unknown is how these macrophages interact with synovial
mesenchymal progenitor cells (sMPCs) in the joint. sMPCs have the potential to undergo chondrogenesis,
but for yet unknown reasons, this ability is decreased in OA patients. In this study, we sought to identify if
alteration of macrophage activity regulates the chondrogenic capacity of sMPCs.
Methods: An explant model was developed using human synovium obtained from normal individuals and
OA patients. These explants were subjected to macrophage depletion and/or cytokine stimulation in order to
regulate/deplete the residing macrophage population. Supernatant was collected following a 12-day treatment
phase and subjected to inflammatory secretome analysis. sMPCs from the explants were subsequently placed
under 21-day chondrogenic differentiation and levels of type II collagen (Col2a), Aggrecan (Acan), and Sox9
gene expression was quantified.
Results: Inflammatory secretome analysis from OA patients revealed the presence of pro-inflammatory analytes
following pro- and anti-inflammatory cytokine stimulation and/or macrophage depletion. Additionally, chondrogenic
differentiation of sMPCs was heterogeneously impacted across all OA patients following pro-/anti-inflammatory
cytokine stimulation and/or macrophage depletion.
Conclusion: Tissue resident synovial macrophages can regulate the chondrogenic differentiation of sMPCs
after cytokine stimulation in a patient specific manner. The secretion profile of OA synovium was also responsive to
cytokine stimulation and/or macrophage depletion as observed by the largely pro-inflammatory milieu upregulated
following cytokine stimulation.
Keywords: Mesenchymal progenitor cell, Chondrogenesis, Macrophage, Synovium, Osteoarthritis
* Correspondence: rkrawetz@ucalgary.ca
1McCaig Institute for Bone and Joint Health, University of Calgary, Cummings
School of Medicine, Calgary, Canada
3Department of Surgery, University of Calgary, Cummings School of
Medicine, Calgary, Canada
Full list of author information is available at the end of the article
© 2016 Fichadiya et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fichadiya et al. Journal of Inflammation  (2016) 13:12 
DOI 10.1186/s12950-016-0120-9
Background
The 2001 discovery of resident mesenchymal progenitor
cells within the synovial membrane (sMPCs) of the joint
presented an opportunity to understand the limited self-
renewal and healing capacity of articular cartilage [1, 2].
Mesenchymal progenitors have the potential to differen-
tiate into bone, fat, and importantly cartilage. How-
ever, in diseases such as osteoarthritis (OA), this
chondrogenic phenotype appears to be modified for
yet unknown reasons [3, 4]. This observation is of
great interest given the potential cell-based therapies
that can be derived using resident sMPCs. Interest-
ingly, it has also been observed that inflammation of
encompassing synovium (synovitis) and corresponding
intimal hyperplasia, subintimal macrophage infiltration
and increased vascularity are not observed without in-
volvement of cartilage disturbance in OA – thereby
implicating the synovium in disease pathogenesis [5–9].
This raises particular questions of whether components of
the synovial inflammatory response are contributing to
the loss of sMPC chondrogenic phenotype.
Macrophages are immune cells derived from the
monocyte lineage that have been demonstrated to
play roles in nearly all aspects of the immune system,
tissue remodeling and wound healing [10]. In recent
years, the regulation and function of macrophage sub-
types has become quite complex, but most agree that
there are at least three distinct subtypes; M0 (or inactive),
M1 (pro-inflammatory) and M2 (anti-inflammatory) [11].
A number of studies have also demonstrated sub-sets
within each of these subtypes that can be distinguished by
cell surface receptors and protein secretion. Macrophages
are the primary inflammatory custodians of the synovial
tissue and can partake in pro- (M1) and anti- (M2) inflam-
matory activities [12]. To date however, there has been
limited characterization of the synovial macrophage; the
components of its inflammatory milieu (across patient
populations and disease severity), and if these cells/prop-
erties regulate/modify sMPC function and/or potential.
Early findings from Bondeson et al. [6] attempting to de-
plete digested OA synovium cultures of macrophages
(using anti-CD14 conjugated beads) found reduced levels
of cytokines known to degrade cartilage, such as TNFα,
IL-1β, IL-6, IL-8, MMP-1 and MMP-3. However, despite
such findings, this study did not assess the sMPC popu-
lation, or changes to its differentiation capacity (if any)
following macrophage depletion. A recent study by
Fahy and colleagues in 2014 explored this issue, expos-
ing sMPCs to conditioned media (CM) from either
digested OA synovium or peripheral blood mono-
nuclear cell-derived M1/M2 macrophages [7]. The
authors found that an anti-inflammatory supernatant
was more conducive to sMPC chondrogenesis com-
pared to a pro-inflammatory supernatant. Such findings
encouraged the present study, with specific interest to as-
sess variations across the patient population.
While the sMPC-macrophage relationship remains
undefined in OA, macrophages have demonstrated
both promoting and hindering roles on MPC activity
in other tissues. For example, tumorigenic MPCs were
found to be activated by macrophages (and their in-
flammatory cytokines) in the tumor site of gastric cancers
[13]. Meanwhile, macrophages were also found to be crit-
ical regulators of MPC osteogenic differention via STAT3
signalling [14]. Additionally, M2-phenotype macrophages
and their associated cytokines supported MPC-graft sur-
vival in the infarct site of damaged heart muscles com-
pared to an M1-phenotype macrophage and associated
cytokines [15]. Such studies are noteworthy, as they help
to illustrate the dynamic MPC-macrophages relationship
across normal and diseases states. The goal of the
present study was to study endogenous synovial macro-
phages and their interactions with sMPC chondrogene-
sis in normal individuals and OA patients using a novel
explant system. By manipulating the presence and/or
phenotype of synovial macrophages, we hypothesized
that the innate chondrogenic capacity of OA sMPCs
could be attenuated. Our findings support this hypoth-
esis in patient-specific manner, and also demonstrate a
systemic shift in the inflammatory phenotype of syn-




Patients with clinical and radiographic OA provided
synovial membrane biopsies through informed con-
sent during non-emergent knee arthroscopy for
meniscal/ligamentous repair at the Peter Lougheed
Centre, in Calgary, AB. Synovial membrane biopsies
from macroscopically normal knees were obtained
from cadavers less the 4 h post-mortem. Tissue do-
nors were received by the Southern Alberta Organ
and Tissue Donation Program (SAOTDP), which ob-
tains the medical history of every donor, including
current medication, previous history of joint diseases,
and other co-morbidities (e.g., cancer, diabetes, in-
flammatory diseases). All donor knees received X-Ray
and macroscopic examination of the joint surfaces.
Any abnormalities (cracking, blistering, darkening, ab-
normal wear) prompted exclusion from the study. All
pertinent information is presented in Table 1. The
procedures followed were in accordance with the eth-
ical standards of the responsible committee on human
experimentation (institutional and national) and with
the Helsinki Declaration of 1975, as revised in 2000
and all ethics were approved by the University of Cal-
gary research ethics board.
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Explant model
Intact synovial biopsies are a physiologically relevant
ex-vivo model to elucidate the sMPC-macrophage re-
lationship in healthy and diseased patients. In this
study, upon receipt of synovium (8 OA and 4 nor-
mal), biopsy samples were seeded in a 24-well cell
culture plate. On days 3, 6, and 9 post-seeding, mac-
rophages within the synovial biopsy samples were
subjected to artificial cytokine stimulation and/or de-
pletion using a cocktail of compounds in order to
observe how such manipulations affected the sMPC popu-
lation (Fig. 1). Specifically, 20 ng/mL of pro-inflammatory
(IFNγ and/or TNFα) and anti-inflammatory (IL-4 and/or
IL-10) cytokines were added because of previously shown
roles in macrophage activation/polarization, and articular
cartilage degradation [16]. These cytokines were added in
the presence or absence of 1000 μM clodronate diso-
dium (Dichloromethylenediphosphonic Acid Disodium
Salt – Sigma) in PBS solution. Clodronate disodium,
a first generation bisphosphonate, was utilized to selectively
Table 1 Summary of demographic information of donor patients (OA & Normal)
OA Patient Age Sex Procedure Additional notes
Patient 1 43 M Right ACL reconstruction Synovitis observed
Patient 2 30 M Right ACL reconstruction Synovitis observed
Patient 3 62 F Right Knee Arthroscopy for torn lateral meniscus Patellar tendon OA & on different cancer medication
Patient 4 50 M Right Knee Arthroscopy & EUAa Advanced (bare bone) OA & candidate for joint replacement
Patient 5 71 M Left Knee Arthroscopy for torn medial meniscus Cartilage surface damage & cracked cartilage on tibial plateau
Patient 6 51 M Right ACL reconstruction
Patient 7 45 M Left ACL reconstruction 2 previous failed ACL reconstructions & synovitis
Patient 8 39 M Left ACL reconstruction
Normal Samples Age Sex
Normal 1 78 M
Normal 2 37 M
Normal 3 54 F
Normal 4 50 F
a Examination under anaesthetic (EUA)
Fig. 1 Explant study experimental flow chart
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deplete macrophages [17–19]. This concentration was
utilized based on a dosage analysis from 100, 1000, and
10,000 μM concentrations (analyzed via flow cytome-
try) which revealed selective macrophage depletion and
sMPC preservation at 1000 μM (Table 2). On day 11
post-seeding, outgrown fibroblastic synoviocytes from
the OA biopsy samples were collected, purified, ex-
panded in culture as described below in “sMPC cul-
ture”. Upon expansion, OA sMPCs from all treatment
groups were subjected to 21-day chondrogenesis. Spe-
cifically, sMPCs were placed under pellet-culture chon-
drogenesis in which 50,000 cells were aggregated into
pellets prior to differentiation. After 21 days, mRNA
was isolated from these pellets and subjected to qRT-PCR.
sMPC culture
An outgrowth method was utilized to culture sMPCs
[20]. Upon receipt of synovium, three (~3 mm3) tissue
explants were cut from the biopsy and seeded in a
24-well culture plate and incubated at 37 °C and 5 %
CO2 with 1 mL of MPC culture media added. The
MPC culture media consisted of DMEM F12 (Invitro-
gen #11965), 10 % Fetal Bovine Serum, 1 % Pen/
Strep, 1 % Non-essential amino acids (NEAA), 0.2 %
β-mercaptoethanol (all Invitrogen, Carlsbad, CA).
Within 11 days post-seeding, outgrown cells were ad-
herent to the plastic and reached 30-40 % confluency
(referring to rough percentage of flask surface area
covered with cells). At this point, cells were gently
dissociated via mechanical stimulation and placed
with 5 mL of MPC media in a T-25 cell culture flask.
Media was changed every 3 days. After cells reached
70 % confluency, the cells were washed, resuspended,
and subjected to magnetic MACs purification entailing (1)
hematopoietic lineage depletion (FCGR3A, CD19, CD3E,
NCAM1, CD14, GYPA, FCGR3B, ITGA2B) and (2) CD90
+ positive selection. Purified cells were then placed in
10 mL of MPC media in T-75 flasks. Media was changed
every three days and cells were passaged when 70-80 %
confluency was reached. Cells passaged a maximum of 3
times were used for chondrogenic differentiation.
qRT-PCR
Following chondrogenesis, mRNA (from biological du-
plicates) was collected using Trizol reagent (Invitrogen)
and converted to cDNA using the High Capacity cDNA
kit (Applied Biosystems, Carlsbad, CA). The cDNA was
probed using pre-validated Taqman primer-sets for
human Aggrecan (Acan), Collagen IIa (Col2a), and
Sox9. All 3 of these genes encode for critical compo-
nents of chondrocyte/cartilage formation. Aggrecan is
a proteoglycan that forms a major component of the
extracellular matrix of articular cartilage. Type II col-
lagen is the base structural protein for articular cartil-
age. Col2a is the gene that encodes for the synthesis
of the pro-alpha1 (II) of type II cartilage. Transcrip-
tion factor SOX9 is a master regulator chondrocyte
differentiation and function. Note: There were bio-
logical duplicates in all experiments and each gene of
interest was run in well-triplicates during qRT-PCR.
Human 18S rRNA was used as the housekeeping gene
in all qRT-PCR experiments based on previously vali-
dated protocols.
Flow cytometry
The endogenous cell populations of the synovium
were characterized using flow cytometry before and
after clodronate treatments in order to determine the
most efficacious dosage of clodronate to use for ex-
plant studies (Table 2). The synovium was first thor-
oughly minced and then placed in heat-inactivated
FBS containing 1 mg/ml collagenase (Sigma) and
digested at 37 °C and 5 % CO2 for 2 h under mild
shaking. After this, supernatant was collected using a
70 μm mesh. This supernatant was rigorously washed
with PBS and fixed with 4 % paraformaldehyde for
5 min. After washing, fixed cells were then incubated
away from light for 1 h with a fluorescent antibodies
for CD68 (FITC, EBioscience) and CD90 (APC,
EBioscience) prior to flow cytometric analysis on an
Invitrogen Attune® Acoustic Focusing Cytometer with
Red/Blue Laser Configurations. An identical protocol
was followed on Day-12 post-seeding of biopsies sam-
ples that were subjected to macrophage depletion via
clodronate disodium treatment.
Luminex
On days 0 and 11 of the sMPC outgrowth phase in the
explant study, samples of the normal and OA biopsy
supernatant were collected and subjected to inflamma-
tory secretome analysis using Luminex. Multiplexed
array technologies allow for multiple concentrations of
specific proteins (cytokines and chemokines were used
in our study) to be quantified within a single biological
Table 2 Effect of Clodronate treatment on macrophage and sMPC populations in synovium (N = 4, all Normal)
Sub-population of interest % Pre-clodronate
treatment
% Post clodronate treatment
100 μM 1000 μM 10000 μM
CD68+/CD90- (Macrophage) 84.23 (+/- 6.17) 14.68 (+/- 4.25) 6.58 (+/- 1.98) 15.88 (+/- 3.01)
CD68-/CD90+ (sMPC) 1.68 (+/- 1.78) 1.14 (+/- 1.36) 3.77 (+/- 1.12) 4.47 (+/- 2.12)
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fluid sample. This is accomplished in a manner that en-
ables direct comparisons of protein concentration values
between samples. In this study, forty-one selected in-
flammatory proteins were examined. Note: Sample ana-
lysis was performed by Eve Technologies (Calgary, AB
Canada) using the Milliplex MAP Human Cytokine/
Chemokine Panel (Millipore) on a Luminex 100 platform
(Luminex Corp., Austin, TX), according to the manufac-
turer’s instructions. All samples were assayed at least in
duplicate and prepared standards were included in all
runs. In the analysis, baseline media analyte levels were
accounted for.
Statistical analysis
GraphPad Prism 6 software was utilized to conduct Mul-
tiple Comparisons Two-Way ANOVA in all qRT-PCR
analysis in which the mean gene expression from each
treatment group was compared against the control row
and SEM was used to assess the standard deviation of
the sampling distribution. Statistical significance was set
at p < 0.05.
For the Luminex data, all samples were normalized
to controls to account for the variance between indi-
viduals. Multivariate analysis of variance (MANOVA)
was applied to test the difference between samples
with and without clodronate, p < 0.05 was considered
statistically significant. Analysis of variance (ANOVA)
with Bonferroni multiple comparison correction was
applied to each cytokine to filter out specifically
which ones are different between samples with and
without clodronate, p < 0.0012 was considered statisti-
cally significant. Principle component analysis (PCA)
was applied and first 9 components (represent >80 %
of total variance) were selected for hierarchical clus-
tering. Dendrograms for 4 conditions were drawn
based on hierarchical cluster results. SPSS 21 (SPSS,




Normal and OA sMPCs that received pro-/anti- in-
flammatory cytokines and/or 1000 μM clodronate
disodium treatment during sMPC outgrowth were
subjected to 21-day chondrogenesis via pellet culture.
As shown in Fig. 2, pooled gene expression data
derived from post-chondrogenic pellet cultures of 4
normal and 8 OA patients revealed that ACAN ex-
pression was only significantly different between nor-
mal and OA in the TNFα plus clondronate group,
while multiple differences were observed in Col2a and
Sox9 expression levels both between normal and OA
across treatment groups (IFNγ, TNFα, IL-4 or IL-10),
and also between the presence or absence of
clodronate within normal and OA treatment groups
(Fig. 2 a-c). Specifically, most of the treatment groups
(IFNγ, TNFα, IL-4 or IL-10) resulted in an increased
expression of chondrogenic marker expression com-
pared to the control (sMPCs derived from untreated
biopsies). IFNγ and IL-4 treatment increased the ex-
pression of Col2a in normal sMPCs, and this effect
was lost when clodronate was added. This same effect
was observed in Sox9 expression with IL-4 treatment,
but not IFNγ treatment (Fig. 2c), however, these
treatment effects were not observed in OA sMPCs.
Un-pooling and examining gene expression patient
by patient revealed more treatment-specific effects in
each patient individually (Fig. 2 d-e). Overall, it can
be observed that the sMPC lines derived from the
normal individuals demonstrate a similar gene expres-
sion profile across the different treatment groups
(IFNγ, TNFα, IL-4 or IL-10) with nearly every treat-
ment resulting in an increase of ACAN, Col2a and
Sox9 expression, with the exception of IL-4 plus clo-
dronate that resulted in a reduction of Col2a and
Sox9 expression (Fig. 2d). sMPCs derived the 8 OA
patients demonstrate a very heterogeneous response
across all treatments (Fig. 2e). Specifically, some OA
patient derived sMPCs demonstrate a global reduction
in chondrogenic gene expression across all or almost
all treatment groups (Fig. 2d, OA patients 3 and 5),
while other patients demonstrated increases in chon-
drogenic gene expression across many treatment
groups (Fig. 2d, OA patients 2 and 8).
Inflammatory secretome analysis (Luminex)
To determine if clodronate treatment had any effect
on the cytokines and chemokines produced from syn-
ovial explants in the presence of cytokine stimulation,
the entire panel of markers (41 analytes) was com-
pared across groups as a complete profile (Table 3).
The normal explants demonstrated no differences in
the cytokine/chemokine profile after treatment with
IFNγ, TNFα, IL-4 or IL-10 in the presence or absence
of clodronate (Table 3). However, the inflammatory
secretome profile of OA explants was different after
clodronate exposure when the explants were stimu-
lated with IFNγ or IL-10, but not TNFα or IL-4
(Table 3). The profiles of the normal and OA ex-
plants after IFNγ, TNFα, IL-4 or IL-10 in the pres-
ence or absence of clodronate was also examined
with principle component analysis (Fig. 3), which
demonstrated that all (or most) of the normal sam-
ples clustered tightly together under each condition
usually surrounded closely by OA samples without
clodronate treatment (Fig. 3). In general, the OA pro-
files were very dispersed compared to the normal
profiles and no clear grouping could consistently be
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observed, with the exception of IL-10 treatment where
there is a clear clustering of OA profiles separated by the
presence or absence of clodronate treatment (Fig. 3). To
analyze the groupings of profiles in more detail, dendro-
gram clustering analysis was undertaken on the inflamma-
tory secretome profiles of all samples under each
treatment group (Fig. 4). As in the PCA, it is clear that all
normal samples cluster together irrespective if clodronate
was added or not. Furthermore, it can be observed that
OA profiles group together based on if clodronate was
added under each treatment group (IFNγ, TNFα, IL-4 or
IL-10) (Fig. 4).
Table 3 Comparison of normal and OA secreted inflammatory
factors in the presence or absence of clodronate after cytokine
stimulation
INFγ TNFα IL-4 IL-10
Normal (N = 4) p = 0.248 p = 0.088 p = 0.851 p = 0.619
OA (N = 8) p = 0.016* p = 0.094 p = 0.130 p = 0.044*
*significance was set at p < 0.05
Fig. 2 Fold-changes of chondrogenic markers in patient derived sMPCs. Expression levels of Aggrecan (Acan) (a), Collagen 2a (Col2a) (b), and
Sox9 (c) were examined with or without cytokine stimulation and/or macrophage depletion (clodronate). All genes were normalized to
the housekeeping gene 18 s and the expression levels of each gene is shown relative to untreated (control) sMPCs following 21-day
pellet culture chondrogenesis. Fold changes in sMPC from normal individuals (d) and OA patients (e) were also examined. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001
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The inflammatory secretome profile of each treat-
ment groups was also examined at the individual
cytokine/chemokine level to determine which proteins
were contributing the differences observed in the
overall profiles (Table 4). Interestingly, although no
differences were observed in the complete profiles of
the normal samples under any conditions, when the
individual proteins were examined it was found that
MCP-1/CCL2 expression was different in the presence
of clodronate after IFNγ, TNFα, IL-4 or IL-10 treat-
ment (Table 4). In the OA samples, a number of proteins
under each condition (IFNγ, TNFα, IL-4 or IL-10) were
determined to be significantly different in the presence vs.
absence of clodronate (Table 4), however, MCP-1/CCL2
was not observed to be different in any OA profiles within
any treatment groups.
Discussion
The aim of the present study was to elucidate the rela-
tionship between synovial macrophages and synovial
MPCs. This was prompted by literature findings that
macrophages are drivers of synovitis and cartilage loss in
OA, and are thus likely candidates to regulate sMPC
chondrogenic differentiation [6, 7, 16, 21]. Other studies
have hypothesized and reported that an M1-macrophage
phenotype and its mediators have anti-chondrogenic
effects [6, 7]. Despite these findings, the present study
is the first of its kind (to our knowledge) to show a
heterogeneous and patient-specific response following
attenuation of macrophages state (via cytokine stimu-
lation or depletion) on sMPC chondrogenesis.
Using a synovial explant model that was to be subjected
to pro- and anti-inflammatory cytokine stimulation and/
Fig. 3 Principle component analysis of cytokines and chemokines secreted from synovial explants. Supernant from 8 OA and 4 normal biopsies
was examined using the Luminex platform. Normal biopsies clustered together in all treatment groups (IFNγ, TNFα, IL-4 or IL-10), regardless of
the presence or absence of clodronate. OA biopsies demonstrated no discernable pattern with the exception of IL-10 treatment in which
all biopsies treated with or without clodronate clustered together
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or macrophage depletion, we first confirmed the presence
of endogenous macrophages using flow cytometry and im-
munofluorescent staining (Table 2 and Additional file 1:
Figure S1). Post 21-day sMPC pellet-culture chondrogene-
sis, qRT-PCR was used to quantify the differentiation
process. Pooled sMPC chondrogenic gene expression data
from 8 OA patients and 4 normal individuals revealed a
non-treatment specific up-regulatory response in the
levels of Acan, Col2a, and Sox9 expression (Fig. 2) when
the explant (not the purified sMPCs) had been treated
with IFNγ, TNFα, IL-4 or IL-10 in the presence or absence
of clodronate. The nature of these findings prompted
closer inspection of the data on an individual patient-
specific basis.
Assessment of the qRT-PCR findings of all 8 OA pa-
tients and 4 normal individuals revealed a heterogeneous
response to all treatments in the OA patient derived
sMPCs, in which macrophages promoted, inhibited, or
had no apparent effect on sMPC chondrogenesis. For
example, in OA Patient 1, sMPC Col2a expression was
increased following TNFα treatment compared to TNFα
treatment alongside macrophage depletion (clodronate),
while, in contrast, sMPCs from OA Patient 4 demon-
strated an increased in Col2a expression in the presence
of TNFα and clodronate. Patient 3 and 5 demonstrated a
near global decrease in chondrogenic gene expression
across all treatment groups, while sMPCs from patients
1, 7 and 8 demonstrate a wide variety of responses to all
Fig. 4 Dendrogram clustering analysis of cytokines and chemokines secreted from synovial explants. Dendrogram analysis of the inflammatory
secretome from normal and OA biopsies after cytokine stimulation with or without clodronate treatment demonstrated that all normal biopsies
grouped together under all treatment groups, while OA samples clustered on the presence/absence of clodronate
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treatment groups (Fig. 2) apparently irrespective of
macrophage presence. Overall, these varying treatment
responses illustrate the heterogeneity between the
sMPCs of OA patients and reinforce the idea that OA is
a spectrum disease with numerous avenues (injury,
metabolic, idiopathic) that can lead to a clinical diagno-
sis [22]. Taken together, it is difficult to interpret the sig-
nificant differences observed in the pooled data because
of the wide and varied response observed within the 8
OA patient samples. This could speak to differences in
age, sex and/or severity of disease in the patients, but
without a larger sample size it would be inappropriate to
stratify and comment on these variables.
The changes in the normal and OA explant inflamma-
tory secretome profiles of during the 12-day treatment
phase provide complementary data to the qRT-PCR ana-
lysis. These findings shed light on the response of nor-
mal and OA synovial tissue to cytokine stimulation
(IFNγ, TNFα, IL-4 or IL-10) in the presence or absence
of macrophage depletion (clodronate). Interestingly, in
normal synovial samples, no profile level changes (all 41
analytes compared together) were observed within or be-
tween treatment groups, however, at the individual pro-
tein level, it was observed that MCP-1/CCL2 was
differentially expressed in under all treatment effects.
Our group has previously implicated MCP-1/CCL2 in
the loss of chondrogenic capacity of synovial MPCs [21].
In that study we were able to demonstrate that MCP-1/
CCL2 doesn’t impede the proliferation MPCs, but only
decreased their chondrogenic capacity. Since MCP-1/
CCL2 was the only protein that appeared to be regulated
by cytokine stimulation with macrophage depletion,
coupled with the observation that only a very few treat-
ments reduced the chondrogenic marker expression in
normal sMPCs; suggests that the normal synovial ex-
plants may have the ability the ‘buffer’ the sMPCs
against cytokine stimulation and this may not dependent
on the presence of synovial macrophages. Additionally,
these results seem to suggest that cytokine stimulation
enhances the chondrogenic differentiation of the
synovial MPCs. While numerous previous studies have
demonstrated that pro-inflammatory cytokines (e.g.
TNFα, IL-1β) inhibit the chondrogenic capacity of stem
cells [23, 24], it is important to recognize that in the
current study, the purified MPCs were never exposed
directly to the cytokines, instead the intact synovial
biopsies were exposed the cytokines, the cytokines
were then removed and MPCs were then derived,
purified and differentiated. This could suggest, that
while certain cytokines can regulate the capacity of
stem cells/MPCs, that when the cells are still within
their niche, interaction with the inflammatory micro-
environment and other tissue resident cells can lead to
distinct outcomes.
The analysis of the OA patient inflammatory secre-
tomes, demonstrated distinct responses compared to the
Table 4 Differentially expressed cytokines in clodronate vs. no-clodronate conditions
Normal (N = 4) OA (N = 8)
INFγ TNFα IL-4 IL-10 INFγ TNFα IL-4 IL-10
MCP-1 MCP-1 MCP-1 MCP-1 IL-10 Eotaxin IL-15 TNF-β
p = 6.2x10-5 p = 3.1x10-5 p = 9.8x10-5 p = 6.7x10-6 p = 2.0x10-6 p = 4.2x10-8 p = 5,6x10-6 p = 4.6x10-5
VEGF MIP-1α Fit-3 L EFG
p = 3.6x10-6 p = 3.6x10-5 p = 0.0002 p = 5.4x10-5
TGFα MIP-1β VEGF MIP-1α
p = 9.0x10-6 p = 0.0008 p = 0.0005 p = 0.0002
GRO IL-4
p = 2.0x10-5 p = 0.0003
RANTES IL-7
p = 4.4x10-5 p = 0.0005
Eotaxin IL-12p40
p = 8.2x10-5 p = 0.0005
MCP-3 MCP-3





After Bonferroni correction p < 0.05/41 = 0.0012
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normal explants. Specifically, a number of cytokines and
chemokines were differentially expressed based on cyto-
kine stimulation and the state of macrophages in the
samples. While there was no single protein that was
found across all treatment groups, MCP-3, MIP-1α, and
VEGF were all observed in half of the treatment groups.
Interestingly, IL-10 was observed in the IFNγ treatment
group, while IL-4 was observed to be differentially regu-
lated in the presence of IL-10. Overall, it would appear
that OA synovium may no longer have the ability to
‘buffer’ the cytokine stimulation and that effect appears
to be regulated by the presence of synovial macrophages.
These findings lend support to the idea that the macro-
phages may have a role to propagate and sustain cyto-
kines being secreted within the synovium, as proposed
in the cytokine theory of OA pathogenesis [25–28].
When the inflammatory secretomes of all the samples
were analyzed by dendrogram clustering analysis, it was
observed that the normal samples always grouped to-
gether regardless of treatment group, or if clodronate
was present or absent (Fig. 4). Interestingly, the OA
samples appeared to group together based on if clodro-
nate was present or absent, however, the same samples
didn’t always group together under each treatment
group (IFNγ, TNFα, IL-4 or IL-10). For one specific ex-
ample; samples from patient 1 and 8 without clodronate
group together in the presence of TNFα, IL-4 and IL-10,
but don’t group together after treatment with IFNγ. This
suggests that explants from different patients respond
differently to specific cytokines and that this is at
least partially dependent on the presence of macro-
phages in that synovial explant. While a sample size
of eight is not large enough to make any definitive
conclusions, this could be part of the reason that OA
patients demonstrate a wide response to anti-cytokine
treatments [29, 30]
Overall, inflammatory secretome data from OA and
normal patients reveal a pathology-dependent response,
where normal patients did not display observable levels
of any analytes (except for MCP-1/CCL2) following
cytokine treatments in the presence or absence of mac-
rophages, while OA patient synovium reacted both to
the cytokine stimulation and macrophage depletion.
Such findings from the normal patients maybe reflective
of state of synovial homeostasis in their joints that is
‘buffered’ to changes in the microenvironment. These
findings are consistent with previous studies, which have
suggested that a healthy synovial joint can maintain a
balanced microenvironment [31]. It would be of interest
to find exactly when the normal synovium loses the abil-
ity to ‘buffer’ cytokine stimulation with the onset and
progression of OA. This would most likely require a
pre-radiographic and pre-symptomatic patient popula-
tion that would be difficult to characterize. Additionally,
since the normal synovial ‘buffering’ ability did not ap-
pear to be solely dependent on the presence of macro-
phages, it would be of interest to elucidate exactly which
cell population(s) are either: providing this capacity in
normal tissues, or alternatively, are responsible for the
dramatic changes in inflammatory response observed in
OA tissues.
This study was not without limitations. The most sali-
ent of which is the number of enrolled patients (8 OA
and 4 normal). Additionally, despite stringent inclusion/
exclusion criteria, the spectrum of disease severity
amongst the OA samples was uncontrolled for in this
study, and was likely reflected (to some extent) in the
degree of heterogeneity observed in the qRT-PCR data
and Luminex. Future studies will seek to increase patient
enrolment such that early, mid, and late stage OA co-
horts could be assessed separately. Beyond this, our
study did not assess how the differentially regulated ana-
lytes in the OA explant supernatant in response to the
cytokine treatments would have ultimately affected the
chondrogenic phenotype of sMPCs thereafter. These
may serve as novel targets to study, as they may be im-
plicated in the sMPC-macrophage relationship.
Conclusion
Using a synovial explant model, we have shown that
the chondrogenic capacity of sMPCs can be regulated
(positively or negatively) by modifying the endogenous
synovial macrophage population (via cytokine stimula-
tion and/or depletion). This study has also revealed
that the inflammatory phenotype of the OA synovium
itself can be responsive to changes in the macrophage
population. These findings lend support to the idea
that macrophages are intricately involved in sMPC
chondrogenesis and are therefore an important cell
type for further investigation, and future therapy
development.
Additional file
Additional file 1: Figure S1. Immunofluorescent examination of
synovial explants with or without clodronate treatment. Whole-mount
immunofluorescent staining of CD68+ Macrophages (FITC). Isolated
synovial biopsies before 12-Day sMPC outgrowth phase (A-B). Isolated
synovial biopsies after 12-Day sMPC outgrowth phase where 1000 μM
clodronate disodium [CLOD (+)] treatment on days 3,6, & 9 post seeding.
(TIF 15841 kb)
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